Pharmacy Practice News: PCT Levels Predict Mortality Risk After Sepsis Diagnosis
May 19, 2017
A recent study found that patients with a procalcitonin decrease of less than 80% during the first four days after diagnosis of severe sepsis or septic shock had a twofold increased risk for death, compared with those who experienced a PCT decrease greater than 80% (Crit Care Med 2017;45:781-789).
The multicenter MOSES (Procalcitonin MOnitoring SEpsis) study investigated use of the PCT assay (B·R·A·H·M·S PCT, Thermo Fisher Scientific) to assess risk for 28-day, all-cause mortality for patients diagnosed with severe sepsis or septic shock. The researchers enrolled a total of 858 adult patients diagnosed with sepsis or septic shock from 13 sites.
As a result of the MOSES study, Thermo Fisher Scientific received expanded FDA clearance for its B·R·A·H·M·S PCT biomarker assay for sepsis risk assessment.